Literature DB >> 7541447

Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors.

R A Prayson1, K Khajavi, Y G Comair.   

Abstract

Gangliogliomas are generally low grade neoplasms composed of mixtures of neoplastic glial and neuronal elements whose origin and exact nature are still controversial. We studied a series of 60 intracranial gangliogliomas looking for coexistent cortical architectural abnormalities (cortical dysplasia, microdysgenesis) and to determine if tumor behavior correlates with MIB1 (marker of cellular proliferation) labeling. The patients included 34 males and 26 females who ranged in age from 6 months to 55 years (mean 20 years). Thirty-eight tumors (63%) were located in the temporal lobe and 6 (10%) in the frontal lobe. Fifty-four patients (90%) presented with seizures (most with intractable epilepsy) and the duration of seizures ranged from 1 to 38 years (mean 14 years). In all cases, the predominant glioma component resembled a low grade fibrillary astrocytoma. In 14 tumors (23%), an oligodendroglial component was present. In one case, the glial component resembled an anaplastic astrocytoma. The tumors were characterized variously by perivascular chronic inflammation (N = 45, 75%), vascular proliferation (N = 36, 60%), granular bodies (N = 54, 90%), binucleated neurons (N = 36, 60%), calcification (N = 28, 47%), and cystic degeneration (N = 26, 43%). Meningeal involvement by tumor was observed in five (8%) cases. In 38 patients, sufficient tissue was resected to evaluate for the presence of concomitant cortical architectural abnormalities. Cortical architectural abnormalities were identified near to but clearly separate from the tumor in 19 (50%) patients. Only four patients including the anaplastic tumor died with tumor progression. MIB1 indices (positive tumor cells/1,000 tumor cells counted) in 54 cases ranged from 0 to 10.2 (mean 1.1 +/- 1.0).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541447     DOI: 10.1097/00005072-199507000-00005

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  19 in total

1.  Freiburg neuropathology case conference: cystic mass lesions of the temporal and occipital lobes in an elderly patient.

Authors:  C A Taschner; O Staszewski; M Pinsker; S El Shikh; M Prinz
Journal:  Clin Neuroradiol       Date:  2011-11       Impact factor: 3.649

2.  Aberrant TP53 protein accumulation in the neuronal component of ganglioglioma.

Authors:  Takao Fukushima; Yoichi Katayama; Takao Watanabe; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 3.  Gamma Knife treatment of low-grade gliomas in children.

Authors:  Murat Şakir Ekşi; Baran Yılmaz; Akın Akakın; Zafer Orkun Toktaş; Ahmet Cemil Kaur; Mustafa Kemal Demir; Türker Kılıç
Journal:  Childs Nerv Syst       Date:  2015-07-15       Impact factor: 1.475

4.  Survivin expression in ganglioglioma.

Authors:  Audrey Rousseau; Michèle Kujas; Anne-Marie Bergemer-Fouquet; Rémy van Effenterre; Jean-Jacques Hauw
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

5.  [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms.

Authors:  D S Rosenberg; G Demarquay; A Jouvet; D Le Bars; N Streichenberger; M Sindou; N Kopp; F Mauguière; P Ryvlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

Review 6.  Malignant ganglioglioma: case report and review of literature.

Authors:  Ryan DeMarchi; Suzy Abu-Abed; David Munoz; R Loch Macdonald
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

7.  Dysembryoplastic neuroepithelial tumors: nonspecific histological forms -- a study of 40 cases.

Authors:  C Daumas-Duport; P Varlet; S Bacha; F Beuvon; P Cervera-Pierot; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

8.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Authors:  Margaret J Dougherty; Mariarita Santi; Marcia S Brose; Changqing Ma; Adam C Resnick; Angela J Sievert; Phillip B Storm; Jaclyn A Biegel
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

Review 9.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

10.  Accuracy of distinguishing between dysembryoplastic neuroepithelial tumors and other epileptogenic brain neoplasms with [¹¹C]methionine PET.

Authors:  Sylvain Rheims; Sebastià Rubi; Sandrine Bouvard; Emilien Bernard; Nathalie Streichenberger; Marc Guenot; Didier Le Bars; Alexander Hammers; Philippe Ryvlin
Journal:  Neuro Oncol       Date:  2014-03-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.